JP2023513679A5 - - Google Patents
Info
- Publication number
- JP2023513679A5 JP2023513679A5 JP2022548056A JP2022548056A JP2023513679A5 JP 2023513679 A5 JP2023513679 A5 JP 2023513679A5 JP 2022548056 A JP2022548056 A JP 2022548056A JP 2022548056 A JP2022548056 A JP 2022548056A JP 2023513679 A5 JP2023513679 A5 JP 2023513679A5
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- unsubstituted
- atoms
- hydrogen
- optionally replaced
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025172009A JP2026010068A (ja) | 2020-02-04 | 2025-10-10 | 中枢神経系障害の治療のためのセロトニン作動性幻覚薬としてのシロシン誘導体 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062969934P | 2020-02-04 | 2020-02-04 | |
| US62/969,934 | 2020-02-04 | ||
| PCT/CA2021/050123 WO2021155468A1 (en) | 2020-02-04 | 2021-02-04 | Psilocin derivatives as serotonergic psychedelic agents for the treatment of cns disorders |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025172009A Division JP2026010068A (ja) | 2020-02-04 | 2025-10-10 | 中枢神経系障害の治療のためのセロトニン作動性幻覚薬としてのシロシン誘導体 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023513679A JP2023513679A (ja) | 2023-04-03 |
| JP2023513679A5 true JP2023513679A5 (enExample) | 2024-02-07 |
Family
ID=77199666
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022548057A Pending JP2023513680A (ja) | 2020-02-04 | 2021-02-04 | 中枢神経系障害の治療のためのセロトニン作動性幻覚薬としてのシロシン誘導体 |
| JP2022548056A Pending JP2023513679A (ja) | 2020-02-04 | 2021-02-04 | 中枢神経系障害の治療のためのセロトニン作動性幻覚薬としてのシロシン誘導体 |
| JP2024015076A Pending JP2024054193A (ja) | 2020-02-04 | 2024-02-02 | 中枢神経系障害の治療のためのセロトニン作動性幻覚薬としてのシロシン誘導体 |
| JP2025172009A Pending JP2026010068A (ja) | 2020-02-04 | 2025-10-10 | 中枢神経系障害の治療のためのセロトニン作動性幻覚薬としてのシロシン誘導体 |
| JP2025243928A Pending JP2026053405A (ja) | 2020-02-04 | 2025-12-09 | 中枢神経系障害の治療のためのセロトニン作動性幻覚薬としてのシロシン誘導体 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022548057A Pending JP2023513680A (ja) | 2020-02-04 | 2021-02-04 | 中枢神経系障害の治療のためのセロトニン作動性幻覚薬としてのシロシン誘導体 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024015076A Pending JP2024054193A (ja) | 2020-02-04 | 2024-02-02 | 中枢神経系障害の治療のためのセロトニン作動性幻覚薬としてのシロシン誘導体 |
| JP2025172009A Pending JP2026010068A (ja) | 2020-02-04 | 2025-10-10 | 中枢神経系障害の治療のためのセロトニン作動性幻覚薬としてのシロシン誘導体 |
| JP2025243928A Pending JP2026053405A (ja) | 2020-02-04 | 2025-12-09 | 中枢神経系障害の治療のためのセロトニン作動性幻覚薬としてのシロシン誘導体 |
Country Status (12)
| Country | Link |
|---|---|
| US (10) | US20220024956A1 (enExample) |
| EP (2) | EP4100390A4 (enExample) |
| JP (5) | JP2023513680A (enExample) |
| KR (3) | KR20220137081A (enExample) |
| CN (3) | CN115974757A (enExample) |
| AU (2) | AU2021217424A1 (enExample) |
| BR (2) | BR112022015375A2 (enExample) |
| CA (2) | CA3166936A1 (enExample) |
| IL (2) | IL295364B1 (enExample) |
| MX (2) | MX2022009527A (enExample) |
| PH (1) | PH12022551981A1 (enExample) |
| WO (2) | WO2021155468A1 (enExample) |
Families Citing this family (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201907871D0 (en) | 2019-06-03 | 2019-07-17 | Small Pharma Ltd | Therapeutic compositions |
| KR20220082092A (ko) | 2019-11-07 | 2022-06-16 | 스몰 파마 엘티디 | 화합물 |
| KR20220137081A (ko) * | 2020-02-04 | 2022-10-11 | 마인드셋 파마 인크. | Cns 장애의 치료를 위한 세로토닌성 사이키델릭 작용제로서의 실로신 유도체 |
| WO2021226416A1 (en) | 2020-05-08 | 2021-11-11 | Psilera Inc. | Novel compositions of matter and pharmaceutical compositions |
| US12240813B2 (en) | 2020-05-19 | 2025-03-04 | Cybin Irl Limited | Deuterated tryptamine derivatives and methods of use |
| US11773062B2 (en) | 2021-03-22 | 2023-10-03 | Small Pharma Ltd | Deuterated compounds |
| US12042564B2 (en) | 2020-06-02 | 2024-07-23 | Cybin Uk Ltd | Therapeutic solid dosage forms |
| CN119285527A (zh) * | 2020-06-30 | 2025-01-10 | 瑞安神经科学公司 | 色胺前药 |
| CA3188636A1 (en) * | 2020-08-21 | 2022-02-24 | Matthias GRILL | Novel psilocin derivatives having prodrug properties |
| US11406619B2 (en) | 2020-08-28 | 2022-08-09 | Small Pharma Ltd | Injectable formulations |
| US11324762B2 (en) | 2020-10-08 | 2022-05-10 | Lennham Pharmaceuticals, Inc. | Deuterated derivatives of psilocybin and uses thereof |
| WO2022115944A1 (en) | 2020-12-01 | 2022-06-09 | Magicmed Industries Inc. | Carboxylated psilocybin derivatives and methods of using |
| US11660289B2 (en) | 2020-12-01 | 2023-05-30 | Small Pharma Ltd. | Deuterated or partially deuterated N,N-dimethyltryptamine compounds |
| US12521370B2 (en) | 2020-12-01 | 2026-01-13 | Cybin Uk Ltd | Inhalable formulations |
| EP4031529B1 (en) * | 2020-12-01 | 2023-09-27 | Small Pharma Ltd | Deuterated or partially deuterated n,n-dimethyltryptamine compounds |
| EP4255422A4 (en) | 2020-12-03 | 2024-12-18 | Mydecine Innovations Group Inc. | NEW PSILOCIN ANALOGUE COMPOSITIONS AND METHODS OF THEIR SYNTHESIS |
| JP2024500397A (ja) * | 2020-12-18 | 2024-01-09 | コンパス パスファインダー リミテッド | 治療用途のための修飾インドールアルカロイド |
| EP4155306A1 (en) | 2021-01-15 | 2023-03-29 | Beckley Psytech Limited | Neuroactive ergoline analogue |
| US12534441B2 (en) | 2021-01-15 | 2026-01-27 | Beckley Psytech Limited | Tryptamine analogues |
| WO2022155751A1 (en) | 2021-01-22 | 2022-07-28 | Magicmed Industries Inc. | Prenylated psilocybin derivatives and methods of using |
| US11312684B1 (en) | 2021-02-10 | 2022-04-26 | Eleusis Therapeutics Us, Inc. | Pharmaceutically acceptable salts of psilocin and uses thereof |
| AU2022229037A1 (en) * | 2021-03-02 | 2023-09-28 | Mindset Pharma Inc. | Indole derivatives as serotonergic agents useful for the treatment of disorders related thereto |
| US20220370413A1 (en) * | 2021-03-06 | 2022-11-24 | Mind Medicine, Inc. | Formulations of psilocin that have enhanced stability |
| US20220280482A1 (en) * | 2021-03-06 | 2022-09-08 | Mind Medicine, Inc. | Formulations of psilocin that have enhanced stability |
| CN117177959A (zh) * | 2021-03-18 | 2023-12-05 | 赛本爱尔兰有限公司 | 裸头草碱类似物、盐、组合物和使用方法 |
| WO2022195011A1 (en) * | 2021-03-18 | 2022-09-22 | Cybin Irl Limited | Psilocybin analogs, salts, compositions, and methods of use |
| US20240174607A1 (en) * | 2021-03-18 | 2024-05-30 | Cybin Irl Limited | Psilocybin analogs, salts, compositions, and methods of use |
| US12611399B2 (en) | 2021-05-04 | 2026-04-28 | Definium Therapeutics US, Inc. | Movement disorders |
| CA3218110A1 (en) | 2021-05-25 | 2022-12-01 | Majed Fawaz | New n,n-dimethyltryptamine salts and crystalline salt forms |
| KR20240058859A (ko) | 2021-08-12 | 2024-05-03 | 쿨레온 엘엘씨 | 환각성 및 비환각성 세로토닌 수용체 작용제 및 이의 제조 및 사용 방법 |
| JP2024534801A (ja) * | 2021-08-20 | 2024-09-26 | テラン バイオサイエンシズ インコーポレイテッド | サイロシンのプロドラッグ及び誘導体ならびにその使用 |
| US11344564B1 (en) | 2021-08-20 | 2022-05-31 | Lennham Pharmaceuticals, Inc. | Method of treatment based on reduced monoamine oxidase a activity |
| CA3229361A1 (en) * | 2021-08-20 | 2023-02-23 | Abdelmalik Slassi | 3-cycloamino-indole compounds as serotonergic agents useful for the treatment of disorders related thereto |
| US11697638B2 (en) | 2021-09-08 | 2023-07-11 | Small Pharma Ltd | 5-methoxy-N,N-dimethyltryptamine crystalline forms |
| US20240424005A1 (en) * | 2021-11-08 | 2024-12-26 | Nova Mentis Life Science Corp. | DIAGNOSING, MONITORING AND TREATING NEUROLOGICAL DISEASE WITH PSYCHOACTIVE TRYPTAMINE DERIVATIVES AND mRNA MEASUREMENTS |
| US12318477B2 (en) | 2021-11-18 | 2025-06-03 | Cybin Uk Ltd | Injectable and inhalable formulations |
| EP4444698A4 (en) * | 2021-12-10 | 2025-07-09 | Caamtech Inc | PSILOCYBIN DERIVATIVES |
| US20250051278A1 (en) * | 2021-12-14 | 2025-02-13 | Reunion Neuroscience, Inc. | Tryptamine prodrugs |
| WO2023129956A2 (en) | 2021-12-30 | 2023-07-06 | ATAI Life Sciences AG | Dimethyltryptamine analogues as nitric oxide delivery drugs |
| WO2023133873A1 (en) * | 2022-01-17 | 2023-07-20 | Nokia Shanghai Bell Co., Ltd. | Configuration for in-x subnetworks |
| WO2023168023A1 (en) | 2022-03-04 | 2023-09-07 | Reset Pharmaceuticals, Inc. | Co-crystals or salts comprising psilocin |
| WO2023173196A1 (en) | 2022-03-18 | 2023-09-21 | Enveric Biosciences Canada Inc. | C4-carboxylic acid-substituted tryptamine derivatives and methods of using |
| AU2023234202A1 (en) * | 2022-03-18 | 2024-11-07 | Enveric Biosciences Canada Inc. | Salts of c4-carboxylic acid- and c4-carbonothioate-substituted tryptamine derivatives and methods of using |
| US20250281399A1 (en) * | 2022-05-01 | 2025-09-11 | Short Wave Pharma Inc. | A mucoadhesive film comprising a pharmaceutically active agent and uses thereof |
| AU2023269880A1 (en) | 2022-05-10 | 2024-01-18 | Mydecine Innovations Group Inc. | Novel psilocin prodrug compounds and methods of synthesizing the same |
| US12264131B2 (en) | 2022-08-19 | 2025-04-01 | Beckley Psytech Limited | Pharmaceutically acceptable salts and compositions thereof |
| US20260085040A1 (en) * | 2022-09-12 | 2026-03-26 | Bionxt Solutions Inc. | Amino acid and carbohydrate psilocin derivatives |
| WO2024145719A1 (en) * | 2023-01-05 | 2024-07-11 | Reunion Neuroscience Inc. | Improved pharmacokinetics of tryptamine prodrugs |
| US20240269113A1 (en) * | 2023-01-24 | 2024-08-15 | Compass Pathfinder Limited | 3-(2-(DIMETHYLAMINO)ETHYL)-1H-INDOL-4-yl DERIVATIVES |
| US12396981B2 (en) | 2023-03-09 | 2025-08-26 | William Shulman | Methods of using DMT |
| EP4704833A2 (en) * | 2023-04-27 | 2026-03-11 | ATAI Therapeutics, Inc. | Alkoxy and carbamoyl quaternary amine salts as prodrugs of trpytamines |
| US12246005B2 (en) | 2023-06-13 | 2025-03-11 | Beckley Psytech Limited | 5-methoxy-n,n-dimethyltryptamine (5-MeO-DMT) formulations |
| WO2025006703A2 (en) * | 2023-06-27 | 2025-01-02 | University Of Padova | Combination therapies using psilocybin |
| WO2025000051A1 (en) | 2023-06-28 | 2025-01-02 | Psylo Pty Ltd | Pyrrolopyridine compounds for the treatment of mental illnesses |
| WO2025000053A1 (en) | 2023-06-28 | 2025-01-02 | Psylo Pty Ltd | Compounds |
| WO2025019800A1 (en) * | 2023-07-19 | 2025-01-23 | Atai Therapeutics, Inc. | Novel prodrugs and conjugates of dimethyltryptamine and methods of using the same |
| CN121752545A (zh) * | 2023-11-06 | 2026-03-27 | 宜昌人福药业有限责任公司 | 一种n,n-二甲基色胺衍生物及其药物组合物、制备方法和用途 |
| WO2025104491A1 (en) | 2023-11-14 | 2025-05-22 | Mindset Pharma Inc. | Indole derivatives as serotonergic agents useful for the treatment of disorders related thereto |
| US12310974B1 (en) | 2023-12-19 | 2025-05-27 | Samuel Aballea | Method of treating post-traumatic stress disorder with carpipramine |
| WO2025238416A1 (en) * | 2024-05-16 | 2025-11-20 | Mindset Pharma Inc. | Indole derivatives, uses and compositions thereof |
| WO2026024591A1 (en) * | 2024-07-22 | 2026-01-29 | Reunion Neuroscience, Inc. | Tryptamine prodrug solid forms |
Family Cites Families (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1242318A (en) | 1913-12-20 | 1917-10-09 | Sam Brest | Ash sifter and receptacle. |
| US3075992A (en) * | 1958-09-12 | 1963-01-29 | Sandoz Ltd | Esters of indoles |
| US3078214A (en) * | 1958-09-12 | 1963-02-19 | Sandoz Ag | Treatment of mental disturbances with esters of indoles |
| CH373381A (de) | 1959-07-13 | 1963-11-30 | Sandoz Ag | Verfahren zur Herstellung neuer basischer Indol-Derivate |
| CH386422A (de) | 1960-03-30 | 1965-01-15 | Sandoz Ag | Verfahren zur Herstellung neuer Ester der Indol-Reihe |
| GB981192A (en) | 1960-03-30 | 1965-01-20 | Westminster Bank Ltd | Improvements in or relating to 4 hydroxytryptamine esters |
| GB933286A (en) | 1961-03-23 | 1963-08-08 | Lodge Cottrell Ltd | Improvements in and relating to electro-precipitation |
| CH414639A (de) * | 1961-10-20 | 1966-06-15 | Sandoz Ag | Verfahren zur Herstellung neuer heterocyclischer Verbindungen |
| US3202675A (en) | 1961-10-26 | 1965-08-24 | Sterling Drug Inc | 1-benzyl-2, 5-bis (chloromethyl) pyrrolidine and acid-addition salts thereof |
| BE615395A (enExample) | 1962-03-21 | |||
| GB990092A (en) | 1962-10-24 | 1965-04-22 | Roche Products Ltd | Novel indole derivatives and a process for the manufacture thereof |
| US7700612B2 (en) * | 2003-12-23 | 2010-04-20 | Abraxis Bioscience, Llc | Di-ester prodrugs of camptothecin, process for their preparation and their therapeutical applications |
| US7655691B2 (en) * | 2004-09-27 | 2010-02-02 | Sard Howard P | Indole compounds useful as serotonin selective agents |
| CN101395164A (zh) | 2006-01-10 | 2009-03-25 | 罗伊·J·于 | N-(膦酰基烷基)-氨基酸、其衍生物和组合物以及使用方法 |
| EP2014662A1 (de) * | 2007-07-12 | 2009-01-14 | Bayer Schering Pharma Aktiengesellschaft | Indolylalkylthienopyrimidylamine als Modulatoren des EP2-Rezeptors |
| AU2009214724A1 (en) * | 2008-02-11 | 2009-08-20 | Organix Inc. | Indole compounds and methods of use thereof |
| EP2149552A1 (de) * | 2008-07-30 | 2010-02-03 | Bayer Schering Pharma AG | 5,6 substituierte Benzamid-Derivate als Modulatoren des EP2-Rezeptors |
| EP2149551A1 (de) * | 2008-07-30 | 2010-02-03 | Bayer Schering Pharma AG | N-(Indol-3-ylalkyl)-(hetero)arylamidderivate als Modulatoren des EP2-Rezeptors |
| EP2464227A4 (en) * | 2009-08-10 | 2013-02-20 | Galenea Corp | COMPOUNDS AND METHODS OF USE |
| US9556126B2 (en) * | 2013-12-20 | 2017-01-31 | Signal Pharmaceuticals, Llc | Substituted diaminopyrimidyl compounds, compositions thereof, and methods of treatment therewith |
| ES2882588T3 (es) | 2015-03-31 | 2021-12-02 | Turtle Bear Holdings Llc | Actividad antiviral de setas medicinales y sus constituyentes activos |
| WO2016205304A1 (en) * | 2015-06-16 | 2016-12-22 | Signal Pharmaceuticals, Llc | Methods of treatment using substituted diaminopyrimidyl compounds |
| CZ307719B6 (cs) | 2015-12-31 | 2019-03-20 | Vysoká škola chemicko-technologická v Praze | Použití derivátu tryptaminu |
| US20180021326A1 (en) | 2016-07-23 | 2018-01-25 | Paul Edward Stamets | Compositions and methods for enhancing neuroregeneration and cognition by combining mushroom extracts containing active ingredients psilocin or psilocybin with erinacines or hericenones enhanced with niacin |
| EP3687514A4 (en) * | 2017-09-27 | 2021-06-30 | Ohio State Innovation Foundation | METHODS AND COMPOSITIONS FOR INHIBITING STAT3 |
| GB2571696B (en) | 2017-10-09 | 2020-05-27 | Compass Pathways Ltd | Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced |
| MA50786A (fr) * | 2017-10-26 | 2022-04-27 | Blumentech S L | Produit d'association pour le traitement de troubles neurologiques et/ou psychiatriques |
| US12090145B2 (en) | 2018-08-20 | 2024-09-17 | Yale University | Combination therapy for treating or preventing depression or other mood diseases |
| MA54877A (fr) | 2019-01-30 | 2021-12-08 | Diamond Therapeutics Inc | Compositions et méthodes comprenant un agoniste de récepteur 5ht destinées au traitement de troubles psychologiques, cognitifs, comportementaux et/ou d'humeur |
| CA3132731A1 (en) | 2019-03-07 | 2020-09-10 | University Of Padova | Compositions and methods of use comprising substances with neural plasticity actions administered at non-psychedelic/psychotomimetic dosages and formulations |
| GB201907871D0 (en) | 2019-06-03 | 2019-07-17 | Small Pharma Ltd | Therapeutic compositions |
| KR20220082092A (ko) | 2019-11-07 | 2022-06-16 | 스몰 파마 엘티디 | 화합물 |
| CA3160793A1 (en) | 2019-12-04 | 2021-06-10 | Neonmind Biosciences Inc. | Use of psilocin, psilocybin or analogs thereof in weight loss, treatment of obesity and compulsive eating disorder |
| KR20220137081A (ko) * | 2020-02-04 | 2022-10-11 | 마인드셋 파마 인크. | Cns 장애의 치료를 위한 세로토닌성 사이키델릭 작용제로서의 실로신 유도체 |
| CA3166785A1 (en) | 2020-02-05 | 2021-08-12 | Yale University | Psychedelic treatment for headache disorders |
| IL297869A (en) | 2020-05-04 | 2023-01-01 | Tufts College | Synthetic lipid-like agents for administration in the brain |
| US12240813B2 (en) | 2020-05-19 | 2025-03-04 | Cybin Irl Limited | Deuterated tryptamine derivatives and methods of use |
| WO2021234608A1 (en) | 2020-05-19 | 2021-11-25 | Cybin Irl Limited | Deuterated tryptamine derivatives and methods of use |
| US20220169606A1 (en) | 2020-12-01 | 2022-06-02 | Small Pharma Ltd. | Compositions and compounds for bioanalysis |
| EP3902541B1 (en) | 2020-06-02 | 2022-09-14 | Small Pharma Ltd | Therapeutic compositions comprising deuterated or partially deuterated n,n-dimethyltryptamine compounds |
| US20220168274A1 (en) | 2020-12-01 | 2022-06-02 | Small Pharma Ltd. | Parenteral Formulation |
| CN119285527A (zh) | 2020-06-30 | 2025-01-10 | 瑞安神经科学公司 | 色胺前药 |
| AU2021328671A1 (en) | 2020-08-18 | 2023-02-16 | Cybin Irl Limited | Phenethylamine derivatives, compositions, and methods of use |
| CA3188636A1 (en) * | 2020-08-21 | 2022-02-24 | Matthias GRILL | Novel psilocin derivatives having prodrug properties |
| JP7422474B2 (ja) | 2020-08-28 | 2024-01-26 | サイビン ユーケー リミテッド | 注射用製剤 |
| US11000534B1 (en) | 2020-10-08 | 2021-05-11 | Lennham Pharmaceuticals, Inc. | Deuterated derivatives of psilocybin and uses thereof |
| US11324762B2 (en) | 2020-10-08 | 2022-05-10 | Lennham Pharmaceuticals, Inc. | Deuterated derivatives of psilocybin and uses thereof |
| WO2022117640A1 (en) | 2020-12-01 | 2022-06-09 | Small Pharma Ltd | Inhalable formulations |
| EP4031529B1 (en) | 2020-12-01 | 2023-09-27 | Small Pharma Ltd | Deuterated or partially deuterated n,n-dimethyltryptamine compounds |
| EP4255422A4 (en) * | 2020-12-03 | 2024-12-18 | Mydecine Innovations Group Inc. | NEW PSILOCIN ANALOGUE COMPOSITIONS AND METHODS OF THEIR SYNTHESIS |
| KR20230109765A (ko) * | 2020-12-09 | 2023-07-20 | 캄테크, 인크. | 다이알킬 트립타민 및 이의 치료적 용도 |
| JP2024500397A (ja) * | 2020-12-18 | 2024-01-09 | コンパス パスファインダー リミテッド | 治療用途のための修飾インドールアルカロイド |
-
2021
- 2021-02-04 KR KR1020227030603A patent/KR20220137081A/ko active Pending
- 2021-02-04 JP JP2022548057A patent/JP2023513680A/ja active Pending
- 2021-02-04 AU AU2021217424A patent/AU2021217424A1/en active Pending
- 2021-02-04 CA CA3166936A patent/CA3166936A1/en active Pending
- 2021-02-04 KR KR1020247004116A patent/KR20240023678A/ko active Pending
- 2021-02-04 MX MX2022009527A patent/MX2022009527A/es unknown
- 2021-02-04 CA CA3166933A patent/CA3166933A1/en active Pending
- 2021-02-04 IL IL295364A patent/IL295364B1/en unknown
- 2021-02-04 JP JP2022548056A patent/JP2023513679A/ja active Pending
- 2021-02-04 AU AU2021215811A patent/AU2021215811A1/en active Pending
- 2021-02-04 BR BR112022015375A patent/BR112022015375A2/pt unknown
- 2021-02-04 KR KR1020227030616A patent/KR20220137083A/ko active Pending
- 2021-02-04 CN CN202310101242.9A patent/CN115974757A/zh active Pending
- 2021-02-04 EP EP21750671.6A patent/EP4100390A4/en active Pending
- 2021-02-04 IL IL295371A patent/IL295371B1/en unknown
- 2021-02-04 CN CN202180026581.4A patent/CN115427395A/zh active Pending
- 2021-02-04 MX MX2022009526A patent/MX2022009526A/es unknown
- 2021-02-04 WO PCT/CA2021/050123 patent/WO2021155468A1/en not_active Ceased
- 2021-02-04 CN CN202180026575.9A patent/CN115397810A/zh active Pending
- 2021-02-04 EP EP21751268.0A patent/EP4100391A4/en active Pending
- 2021-02-04 BR BR112022015377A patent/BR112022015377A2/pt unknown
- 2021-02-04 WO PCT/CA2021/050125 patent/WO2021155470A1/en not_active Ceased
- 2021-02-04 PH PH1/2022/551981A patent/PH12022551981A1/en unknown
- 2021-07-28 US US17/387,883 patent/US20220024956A1/en active Pending
- 2021-07-28 US US17/387,845 patent/US11427604B2/en active Active
-
2022
- 2022-05-13 US US17/743,718 patent/US11597738B2/en active Active
- 2022-06-06 US US17/833,341 patent/US11591353B2/en active Active
- 2022-12-12 US US18/079,617 patent/US12054505B2/en active Active
-
2023
- 2023-01-27 US US18/102,359 patent/US20230167141A1/en not_active Abandoned
- 2023-02-15 US US18/109,890 patent/US20230203070A1/en not_active Abandoned
-
2024
- 2024-02-02 JP JP2024015076A patent/JP2024054193A/ja active Pending
- 2024-05-30 US US18/678,114 patent/US12378266B2/en active Active
- 2024-12-16 US US18/982,452 patent/US20250388611A1/en active Pending
-
2025
- 2025-06-11 US US19/235,150 patent/US20260116901A1/en active Pending
- 2025-10-10 JP JP2025172009A patent/JP2026010068A/ja active Pending
- 2025-12-09 JP JP2025243928A patent/JP2026053405A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023513679A5 (enExample) | ||
| JP2023512821A5 (enExample) | ||
| IL295371A (en) | Psilocyin derivatives as serotonergic psychedelics for the treatment of central nervous system disorders | |
| JP2023553094A5 (enExample) | ||
| JP2024508922A5 (enExample) | ||
| JP2023513680A5 (enExample) | ||
| JP2025501630A5 (enExample) | ||
| JP2024508545A5 (enExample) | ||
| JP2025501629A5 (enExample) | ||
| JP6933964B2 (ja) | ヘテロアリール化合物およびそれらの使用方法 | |
| RU2009103307A (ru) | ПРОИЗВОДНЫЕ ИМИДАЗО[1, 2-a]ПИРИДИН-2-КАРБОКСАМИДОВ, ИХ ПОЛУЧЕНИЕ И ПРИМЕНЕНИЕ В ТЕРАПИИ | |
| JP2015523406A5 (enExample) | ||
| JP2021519267A5 (enExample) | ||
| EP2360165A3 (de) | Glucopyranosyl-substituierte Benzol-Derivate, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung | |
| EA033686B1 (ru) | Гетероциклические соединения, применимые в качестве модуляторов tnf-альфа | |
| JP2025513462A5 (enExample) | ||
| JP2019534327A5 (enExample) | ||
| JP2015514073A (ja) | スピロ環式ジヒドロ−チアジンおよびジヒドロ−オキサジンｂａｃｅ阻害剤、ならびにその組成物および使用 | |
| CN110049966A (zh) | 氨基甲酰基苯丙氨醇化合物及其用途 | |
| CA2043671A1 (en) | Pharmacologically active cns compounds | |
| JP2014503576A5 (enExample) | ||
| JP2025513461A5 (enExample) | ||
| KR102531693B1 (ko) | ６，７―디히드로피라졸로［１，５―ａ］피라진―４（５Ｈ）―온 화합물 및 ＭＧＬＵＲ２ 수용체의 음성 알로스테릭 조절제로서의 그 용도 | |
| RU2011103759A (ru) | Замещенные 6-(1-пиперазинил)-пиридазины в качестве антагонистов 5-нт6 рецептора | |
| RU2013124827A (ru) | Производные индола и способ их получения |